Glenmark gets USFDA nod for migraine drug

Glenmark's current portfolio consists of 87 products authorised for distribution in the US market

Pharmaceuticals today said it has received US health regulator's approval to market generic version of Merck's Maxalt MLT tablets, used to treat migraine headaches, in the American market.

Glenmark Generics Inc, USA, a subsidiary of the company, has received final approval from the US Food and Drug Administration (US FDA) for or orally disintegrating tablets (ODT) in strengths of 5 mg and 10 mg, Glenmark Pharma said in a statement.

"The company will commence shipping immediately," it added.

According to Health, for the 12 month period ending March 2013, Rizatriptan ODT achieved sales of $263 million.

Glenmark's current portfolio consists of 87 products authorised for distribution in the US market and 53 abbreviated new drug applications (ANDA)'s are pending approval with the USFDA.

"In addition to these internal filings, continues to identify and explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio," the company added.

Shares of Glenmark were trading at Rs 575 apiece on the in afternoon trade, up 1.13% from their previous close.

image
Business Standard
177 22
Business Standard

Glenmark gets USFDA nod for migraine drug

Glenmark's current portfolio consists of 87 products authorised for distribution in the US market

Press Trust of India  |  New Delhi 



Pharmaceuticals today said it has received US health regulator's approval to market generic version of Merck's Maxalt MLT tablets, used to treat migraine headaches, in the American market.

Glenmark Generics Inc, USA, a subsidiary of the company, has received final approval from the US Food and Drug Administration (US FDA) for or orally disintegrating tablets (ODT) in strengths of 5 mg and 10 mg, Glenmark Pharma said in a statement.



"The company will commence shipping immediately," it added.

According to Health, for the 12 month period ending March 2013, Rizatriptan ODT achieved sales of $263 million.

Glenmark's current portfolio consists of 87 products authorised for distribution in the US market and 53 abbreviated new drug applications (ANDA)'s are pending approval with the USFDA.

"In addition to these internal filings, continues to identify and explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio," the company added.

Shares of Glenmark were trading at Rs 575 apiece on the in afternoon trade, up 1.13% from their previous close.

RECOMMENDED FOR YOU

Glenmark gets USFDA nod for migraine drug

Glenmark's current portfolio consists of 87 products authorised for distribution in the US market

Glenmark Pharmaceuticals today said it has received US health regulator's approval to market generic version of Merck's Maxalt MLT tablets, used to treat migraine headaches, in the American market. Pharmaceuticals today said it has received US health regulator's approval to market generic version of Merck's Maxalt MLT tablets, used to treat migraine headaches, in the American market.

Glenmark Generics Inc, USA, a subsidiary of the company, has received final approval from the US Food and Drug Administration (US FDA) for or orally disintegrating tablets (ODT) in strengths of 5 mg and 10 mg, Glenmark Pharma said in a statement.

"The company will commence shipping immediately," it added.

According to Health, for the 12 month period ending March 2013, Rizatriptan ODT achieved sales of $263 million.

Glenmark's current portfolio consists of 87 products authorised for distribution in the US market and 53 abbreviated new drug applications (ANDA)'s are pending approval with the USFDA.

"In addition to these internal filings, continues to identify and explore external development partnerships to supplement and accelerate the growth of the existing pipeline and portfolio," the company added.

Shares of Glenmark were trading at Rs 575 apiece on the in afternoon trade, up 1.13% from their previous close.
image
Business Standard
177 22
Widgets Magazine

More News

  • Railways raises short distance coal freight Panel on coal requirement by Sasan Power to meet next week
  • Cairn Energy gets over Rs 29,000-cr tax demand Cairn tax dispute: India has to respond by November, says CEO
Widgets Magazine
Widgets Magazine

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard